These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 39156358)

  • 21. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
    Machiels JP; Tao Y; Licitra L; Burtness B; Tahara M; Rischin D; Alves G; Lima IPF; Hughes BGM; Pointreau Y; Aksoy S; Laban S; Greil R; Burian M; Hetnał M; Delord JP; Mesía R; Taberna M; Waldron JN; Simon C; Grégoire V; Harrington KJ; Swaby RF; Zhang Y; Gumuscu B; Bidadi B; Siu LL;
    Lancet Oncol; 2024 May; 25(5):572-587. PubMed ID: 38561010
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Pembrolizumab in Recurrent/Metastatic Squamous Cell Head and Neck Carcinoma: A Multicenter Retrospective Study.
    Okada T; Fushimi C; Matsuki T; Tokashiki K; Takahashi H; Okamoto I; Sato H; Kondo T; Hanyu K; Kishida T; Ito T; Yamashita G; Masubuchi T; Tada Y; Miura K; Omura GO; Yamashita T; Oridate N; Tsukahara K
    Anticancer Res; 2023 Jun; 43(6):2717-2724. PubMed ID: 37247908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Case Report: Severe Immune-Related Cholestatic Hepatitis and Subsequent Pneumonia After Pembrolizumab Therapy in a Geriatic Patient With Metastic Gastric Cancer.
    Yang H; Zhou C; Yuan F; Guo L; Yang L; Shi Y; Zhang J
    Front Med (Lausanne); 2021; 8():719236. PubMed ID: 34712676
    [No Abstract]   [Full Text] [Related]  

  • 24. Real-world Therapeutic Outcomes of the Pembrolizumab Regimen as First-line Therapy for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Single-center Retrospective Cohort Study in Japan.
    Sano D; Tokuhisa M; Takahashi H; Hatano T; Nishimura G; Ichikawa Y; Oridate N
    Anticancer Res; 2022 Sep; 42(9):4477-4484. PubMed ID: 36039457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment.
    Okuno T; Nakashima K; Mitarai Y; Kataoka M; Tobita H; Nagase M; Isobe T; Tsubata Y
    Respir Med Case Rep; 2022; 40():101753. PubMed ID: 36217354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment.
    Okuno T; Nakashima K; Mitarai Y; Kataoka M; Tobita H; Nagase M; Isobe T; Tsubata Y
    Respir Med Case Rep; 2022; 40():101773. PubMed ID: 36408484
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
    Cohen EEW; Soulières D; Le Tourneau C; Dinis J; Licitra L; Ahn MJ; Soria A; Machiels JP; Mach N; Mehra R; Burtness B; Zhang P; Cheng J; Swaby RF; Harrington KJ;
    Lancet; 2019 Jan; 393(10167):156-167. PubMed ID: 30509740
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and network meta-analysis.
    Wang S; Yan L; Yu J; Lu C
    Eur Arch Otorhinolaryngol; 2024 Jul; 281(7):3385-3395. PubMed ID: 38358507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
    Cohen EEW; Bell RB; Bifulco CB; Burtness B; Gillison ML; Harrington KJ; Le QT; Lee NY; Leidner R; Lewis RL; Licitra L; Mehanna H; Mell LK; Raben A; Sikora AG; Uppaluri R; Whitworth F; Zandberg DP; Ferris RL
    J Immunother Cancer; 2019 Jul; 7(1):184. PubMed ID: 31307547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful Treatment with Short-Term Steroid Against Severe Hepatitis Confirmed by Liver Biopsy in a Patient with Advanced Squamous-Cell Lung Cancer Receiving a Combination of Pembrolizumab, Carboplatin, and Nab-Paclitaxel: A Case Report.
    Hayashi A; Nakamichi S; Nakayama Y; Nagano A; Mikami E; Takano N; Tozuka T; Matsumoto M; Miyanaga A; Noro R; Terasaki Y; Kubota K; Seike M; Gemma A
    Onco Targets Ther; 2022; 15():637-642. PubMed ID: 35698605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis of Randomized Clinical Trials.
    Zhang W; Gu J; Bian C; Huang G
    Front Pharmacol; 2021; 12():686876. PubMed ID: 34759817
    [No Abstract]   [Full Text] [Related]  

  • 32. Case Report: SAPHO Syndrome Mimicking Bone Metastases During Treatment With Pembrolizumab for Non-small Cell Lung Cancer.
    Kubo Y; Ito K; Fujiwara Y; Yoshida T; Kusumoto M
    Front Med (Lausanne); 2021; 8():679111. PubMed ID: 34368186
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non-Small-Cell Lung Cancer.
    Shukla NA; Althouse S; Meyer Z; Hanna N; Durm G
    Clin Lung Cancer; 2021 Jul; 22(4):274-281. PubMed ID: 33610454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complete remission of advanced and recurrent cervical cancer with pembrolizumab treatment- 3 case reports.
    Tung HJ; Wang CC; Liu FY; Lai CH
    Taiwan J Obstet Gynecol; 2021 Sep; 60(5):938-941. PubMed ID: 34507680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune-Therapy-Related Toxicity Events and Dramatic Remission After a Single Dose of Pembrolizumab Treatment in Metastatic Thymoma: A Case Report.
    Shen L; Chen H; Wei Q
    Front Immunol; 2021; 12():621858. PubMed ID: 33936037
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An immune-related adverse event of Behcet's-like syndrome following pembrolizumab treatment.
    Chen Q; Li D; Zhang G; Zhong J; Lin L; Liu Z
    BMC Pulm Med; 2024 Apr; 24(1):166. PubMed ID: 38575924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.
    Sacco AG; Chen R; Worden FP; Wong DJL; Adkins D; Swiecicki P; Chai-Ho W; Oppelt P; Ghosh D; Bykowski J; Molinolo A; Pittman E; Estrada MV; Gold K; Daniels G; Lippman SM; Natsuhara A; Messer K; Cohen EEW
    Lancet Oncol; 2021 Jun; 22(6):883-892. PubMed ID: 33989559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.
    Atkins MB; Plimack ER; Puzanov I; Fishman MN; McDermott DF; Cho DC; Vaishampayan U; George S; Olencki TE; Tarazi JC; Rosbrook B; Fernandez KC; Lechuga M; Choueiri TK
    Lancet Oncol; 2018 Mar; 19(3):405-415. PubMed ID: 29439857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study.
    Cho BC; Braña I; Cirauqui B; Aksoy S; Couture F; Hong RL; Miller WH; Chaves-Conde M; Teixeira M; Leopold L; Munteanu M; Ge JY; Swaby RF; Hughes BGM
    BMC Cancer; 2024 Jul; 23(Suppl 1):1254. PubMed ID: 39054467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Case of Recurrent Metastatic Parotid Acinic Cell Carcinoma Responsive to Pembrolizumab.
    Yamashita G; Okamoto I; Shimizu A; Tokashiki K; Okada T; Sato H; Tsukahara K
    In Vivo; 2022; 36(2):1047-1051. PubMed ID: 35241570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.